20 de marzo de 2019
  • Martes, 19 de Marzo
  • 17 de noviembre de 2008

    First Pivotal Trials Begin for Boehringer Ingelheim's Novel Triple Angiokinase Inhibitor Vargatef(TM) (BIBF 1120) (1)


    About ECOG
    Grade Eastern Cooperative Oncology Group (ECOG) performance status
    0 Fully active, able to carry on all pre-disease
    performance without restriction
    1 Restricted in physically strenuous activity but
    ambulatory and able to carry out work of a light or
    sedentary nature, e.g., light house work, office work
    2 Ambulatory and capable of all self-care but unable to
    carry out any work activities. Up and about more than
    50% of waking hours
    3 Capable of only limited self-care, confined to bed or
    chair more than 50% of waking hours
    4 Completely disabled. Cannot carry on any self-care.
    Totally confined to bed or chair
    5 Dead

    About Boehringer Ingelheim in Oncology

    Building on scientific expertise and excellence in the fields of pulmonary and cardiovascular medicine, metabolic disease, neurology, virology and immunology, Boehringer Ingelheim has embarked on a major research programme to develop innovative cancer drugs.

    Working in close collaboration with the international scientific community and a number of the world's leading cancer centres, Boehringer Ingelheim is committed to discovering and developing novel cancer treatments that have the potential to provide significant clinical and quality of life benefits for patients. This commitment is underpinned by using advances in science to develop a range of targeted therapies in areas of medical need, including various solid tumours and haematological cancers.

    The current focus of research includes compounds in three areas: angiogenesis inhibition, signal transduction inhibition and cell-cycle kinase inhibition. Tovok(TM) (BIBW 2992), a novel representative of the new generation of tyrosine kinase inhibitors, entered phase IIb/III clinical development in NSCLC earlier in 2008 and was granted Fast Track designation by the FDA. Its second pivotal trial LUX-Lung 3, will commence soon.

    In the area of cell-cycle kinase inhibition, Boehringer Ingelheim is developing novel, potent and highly selective inhibitors of polo-like kinase 1 (Plk1), a protein that is involved in the processes of cell division. These molecules are in the early stages of clinical development.

    The clinical trial programme for Boehringer Ingelheim's oncology portfolio is themed around the concept of light, and the notion that the company is committed to illuminating research and development within the field of oncology. All trials are named accordingly, as variations on this overall theme.

    Boehringer Ingelheim

    (CONTINUA)